據報復宏漢霖(02696.HK)與強生等就出售抗癌藥物專利進行談判
《彭博》引述消息人士報道,復宏漢霖(02696.HK)正在與強生(JNJ.US)及羅氏藥廠等跨國製藥公司,就出售一種實驗性抗癌藥物HLX43的專利進行談判。
HLX43為靶向PD-L1抗體偶聯藥物,於上月獲美國食品藥品管理局(FDA)批准開展用於治療胸腺癌的1期臨床試驗。
報道稱,根據該協議,上復宏漢霖可能獲得至少數億美元的預付款,之後還將根據藥品的表現獲得里程碑付款。目前談判仍在進行中,隨著HLX43有更多數據公布,復宏漢霖可能會要求更高的價格。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.